RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department

Similar documents
Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics. Yen Tibayan, M.D. Division of Cardiovascular Medicine

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations.

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology

Management of Acute Coronary Syndrome / NSTEMI

Chest Pain. Acute Myocardial Infarction: Differential Diagnosis and Patient Management. Common complaint in ED. Wide range of etiologies

38 year old female with mild obesity. She is planning an exercise program to loose weight. She has no other known risk factors for CAD.

Redefining the NSTEACS pathway in London

EMR Tutorial Acute Coronary Syndrome

Non Invasive Testing for CAD

Methods and formulas used to calculate the GRACE Risk Scores for patients presenting to hospital with an acute coronary syndrome:

Osama Jarkas. in Chest Pain Patients. STUDENT NAME: Osama Jarkas DATE: August 10 th, 2015

Listen to your heart: Good Cardiovascular Health for Life

Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

NAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3

Cardiovascular diseases. pathology

Provider Checklist-Outpatient Imaging. Checklist: Nuclear Stress Test, Thallium/Technetium/Sestamibi (CPT Code )

Efficient Evaluation of Chest Pain

Acute Coronary Syndrome. What Every Healthcare Professional Needs To Know

Perioperative Cardiac Evaluation

Chest Pain in Young Athletes. Christopher Davis, MD, PhD Pediatric Cardiology Rady Children s Hospital San Diego cdavis@rchsd.

GENERAL HEART DISEASE KNOW THE FACTS

URN: Family name: Given name(s): Address:

Tips and Tricks to Demystify 12 Lead ECG Interpretation

REFERRAL HOSPITAL. The Importance of Door In Door Out Time DIDO

Cilostazol versus Clopidogrel after Coronary Stenting

Section 8: Clinical Exercise Testing. a maximal GXT?

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg

Main Effect of Screening for Coronary Artery Disease Using CT

CHAPTER 9 DISEASES OF THE CIRCULATORY SYSTEM (I00-I99)

Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History

INTRODUCTION TO EECP THERAPY

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania

Stent for Life Initiative How can we improve system delay and patients delay in STEMI

Implementing a Prehospital 12-Lead Program

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November :38

Perioperative Risk Stratification for Noncardiac Surgical Patients with Cardiac Diagnosis. Michael A. Blazing

STROKE PREVENTION IN ATRIAL FIBRILLATION

Evaluating ED Patients with Transient Ischemic Attack: Inpatient vs. Outpatient Strategies

MANAGEMENT AKUTES KORONARSYNDROM: RISIKOSTRATIFIZIERUNG UND THERAPIE. Peter Wenaweser Universitätsklinik für Kardiologie

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

Addendum to Clinical Review for NDA

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute

Acute Coronary Syndromes Education for Healthcare Providers. Hani Kozman, MD Cardiology Division SUNY Upstate Medical University

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial

CHEST PAIN EVALUATION TOOL

FFR CT : Clinical studies

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

Diagnostic and Therapeutic Procedures

Antiplatelet and Antithrombotics From clinical trials to guidelines

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators

All patients presenting to the Emergency Department with symptoms suggestive of

2002 by the American College of Cardiology and the American Heart Association, Inc.

Networking for optimal treatment of STEMI and NSTEMI. European Stent for life Project

4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa Objectives. No disclosures, no conflicts

DIAGNOSTIC CRITERIA OF AMI/ACS

Educational Goals & Objectives

Acute heart failure may be de novo or it may be a decompensation of chronic heart failure.

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

Translating Science to Health Care: the Use of Predictive Models in Decision Making

A PATIENT S GUIDE TO SECONDARY PREVENTION IN ACUTE CORONARY SYNDROME (ACS)

CARDIOLOGY ROTATION GOALS AND OBJECTIVES

Rivaroxaban for acute coronary syndromes

Coronary Heart Disease (CHD) Brief

Atrial Fibrillation Management Across the Spectrum of Illness

The Role of Insurance in Providing Access to Cardiac Care in Maryland. Samuel L. Brown, Ph.D. University of Baltimore College of Public Affairs

Heart Attack: What You Need to Know

Nurse Practitioner. CLINICAL PROTOCOL Chest Pain

STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE

Emergency Management Strategies for Acute Myocardial Infarction - Code R at LGH

PREVENTION IN THE CLINICAL SETTING

Advancing ACS Diagnosis Using Serial Troponin Testing

ESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease

Medical Tourism - The Role of Intervals inCardiovascular Cancer

3/2/2010 Post CABG R h e bili a i tat on Ahmed Elkerdany Professor o f oof C ardiac Cardiac Surgery Ain Shams University 1

Cardiac Biomarkers: When to Test? Physician Perspective

Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot

Cardiac Rehabilitation (Outpatient Phase II) Corporate Medical Policy. Medical Policy

Monitoring acute coronary syndrome using national hospital data An information paper on trends and issues

Official Online ACLS Exam

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES

Utilizing the Cath Lab for Cardiac Arrest

The new Heart Failure pathway

Issues and Challenges in ACS Management. Dr.Nakul Sinha MD.DM, FACC. Sahara Hospital, LUCKNOW

Cardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better

Transcription:

RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department Sohil Pothiawala FAMS (EM), MRCSEd (A&E), M.Med (EM), MBBS Consultant Dept. of Emergency Medicine Singapore General Hospital

Overview Definition of Acute coronary syndrome (ACS) Why risk stratification? Factors incorporated in risk stratification History Examination Diagnostic studies eg. ECG, Biochemical cardiac markers, other tests Scoring systems

Definition Acute coronary syndrome Constellation of clinical symptoms that are compatible with acute myocardial ischemia Encompasses a spectrum from AMI NSTEMI UA

Why risk stratification Determine the likelihood of symptoms representing ACS v/s other differential diagnosis Select appropriate Therapy (PCI v/s medical) Select site of care (ICU v/s telemetry) Determine the risk of adverse outcomes (eg death, MI, stroke, CHF, recurrent ischemia, arrhythmias) Risk stratification should be ongoing at admission, 6-8 hrs, 24hrs, discharge

History 5 most important factors that relate to the likelihood of ischemia due to CAD Nature of the anginal symptoms/equivalents Prior Hx of CAD Sex Age Number of traditional risk factors present

BEWARE women, diabetics, renal pts and elderly Description of chest pain alone cannot be used to rule out CAD Traditional risk factors are only weakly predictive of likelihood of acute ischemia, but help predict poor outcomes

Atypical Presentations of ACS Most frequent angina equivalents - SOB>Weakness>Unusual Fatigue>Sweats>Dizziness Associated symptoms most predictive of MI: ED observed sweating>vomiting>radiation to both arms>radiation to R arm Radiation to the L arm did not increase the likelihood of MI in recent study in Resuscitation, 2010 7% of pts with ACS will have pleuritic chest pain 7% of pts have their pain partially or fully reproduced on chest wall palpation Conclusion: Atypical is the new Typical ie. Atypical presentations of ACS are common

Value of Physical Examination Exclude other diagnoses pulse deficit, new aortic regurg murmur and neuro deficit in aortic dissection unilateral decreased air entry and JVD in tension pneumothorax friction rub, muffled heart sound and JVD in pericarditis with tamponade Prognostication look for signs of CCF (JVD, S3, crackles and peripheral edema) has worse Px aortic stenosis murmur (critical AS with ischemia carries very poor prognosis) new mitral regurg murmur (ominous sign of papillary muscle rupture)

ECG A completely normal ECG in a patient with chest pain DOES NOT exclude the possibility of ACS 1-6% proven to have AMI, 4% unstable angina Single ECG for AMI sensitivity of 60%, specificity 90% Represents single point in time needs to be read in context Trend towards increased mortality when ischemia not initially diagnosed on ECG Serial ECGs or ECG adjuncts more sensitive than the presenting ECG alone

Biochemical cardiac markers Useful in both the diagnosis of myocardial necrosis (STEMI/NSTEMI) as well as treatment implications Prognostically, there is a quantitative relationship between the magnitude of elevation of marker levels and the risk of an adverse event

Cardiac Biomarkers 2 sets of Troponins (6-8hrs apart) are indicated for all pts (except those that have isolated CP >12hrs prior to ED visit who only need 1 Troponin) High-sensitive Troponins turn positive sooner than older Troponins - 1hr and 3hr post CP high-sensitive Troponin has a near 100% sensitivity to rule out MI in low risk patients However, they are less specific than the traditional Troponins (N Eng J Med, Aug 2009) Differentials of elevated Troponin: PE, myocarditis, sepsis, post-cardioversion, CHF Troponin levels reflect increased risk of death/mi regardless of renal dysfunction (N Engl J Med 2002; 346:2047-2052) When to use CK-MB? CK-MB returns to baseline in 2-4days v/s Troponin in 1 wk. So if pt presents with CP 5 days after being discharged with MI, the CK-MB is helpful to determine whether the Troponin rise is from the MI that occurred 5 days ago v/s pt has reinfarcted today

IMAGING MODALITIES Multi-detector CT for coronary calcification Coronary CT angiography Cardiac MRI Diagnostic Utility of Recent Cardiac Testing for ED Patients with Chest Pain up to 2/3 of AMIs caused by stenotic plaques <50% occlusive, so tests based on stenosis can be misleading treadmill stress test has only 68% sensitivity and 77% specificity for single vessel disease a recent negative angiogram does not rule out ACS in the ED patient

Risk Scores IS C H A E M IA TIMI (Thrombolysis in Myocardial Infarction) PURSUIT (Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy) GRACE (Global Registry of Acute Cardiac Events) B L E E D I N G HEART CRUSADE (Can Rapid risk stratification of Unstable angina patients supress ADverse outcomes with Early implementation of the ACC/AHA guidelines) ACUITY (Acute catheterization and Urgent Intervention Triage Strategy)

Historical Age 65 TIMI Risk Score increased mortality with increasing score ~40% all cause mortality at 14 days for patients requiring urgent revascularisation 1 point 3 or more CHD risk factors 1 point Known CHD (stenosis 50%) Use of aspirin in previous 7 days 1 point 1 point Presentation At least 2 angina events in past 24 hrs 1 point ST deviation 0.5mm 1 point cardiac markers (TnT or CK-MB) 1 point Risk Score Total (0-7) Antman EM, et al. The TIMI risk score for unstable angina/non-st elevation MI. JAMA 2000;284:835-842

Why use the TIMI Risk Score? - Means of integrating all clinical factors and markers to be a comprehensive risk stratification tool - Developed on basis on endpoints of death, MI or severe recurrent ischemia v/s mortality - Well validated in clinical trials - Simple tool to predict benefit of therapies

PURSUIT Risk factors for AMI Age (decade) Gender Highest Canadian Cardiovascular Society angina classification in previous 6 weeks Heart rate Systolic blood pressure Signs of heart failure (eg, rales) ST depression on presenting ECG Score range 0-25 Predicts 30-day risk Boersma E, et al. for the PURSUIT investigators. Circulation 2000;101:2557-67

GRACE Score for in-hospital mortality Killip heart failure class Systolic blood pressure Heart rate Age Creatinine level Cardiac arrest at admission ST-segment deviation Elevated cardiac enzyme levels Granger CB, et al. Predictors of hospital mortality in the GRACE. Arch Intern Med. 2003; 163:2345-53

HEART score History ECG Age Risk Factors Troponin Score is the sum of these 5 factors Score 0-3: discharge (2.5% risk of Adverse Event) 4-6: observation (20% risk) >7: invasive strategies (72% risk) Six AJ, et al. Chest pain in the emergency room:value of the HEART score. Neth Heart J. 2008;16(6):191-196

WHICH MODEL IS MOST APPROPRIATE?? ACC/AHA GUIDELINES: Risk stratification models useful in decision making with regard to treatment options TIMI vs GRACE vs PURSUIT vs HEART PURSUIT & GRACE risk scores allow better discrimination of in hospital and 1 year mortality in patients compared to TIMI. (Andrew et al, Risk scores for risk stratification in ACS )

Summary ED evaluation is the key Risk stratification in ACS involves assessment of History Examination ECG Biochemical cardiac markers Risk Stratification Scores Risk stratification will determine the need for appropriate management and assessing prognosis

THANK YOU